Department of Microbial Therapy

Head of Department – Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor Alexander Suvorov

MAIN GOALS OF THE DEPARTMENT:

  • Study of the GURSA strain in animal models. Creation of oncolytic bacterial and viral strains for the treatment of intestinal and pancreatobiliary neoplasms, as well as brain tumors.
  • Development of an approach to improving the long-term results of treatment of cancer patients through personalized microbial therapy.
  • Research aimed at personalized selection of autoprobiotics for patients with oncological and oncohematological profile.
  • Analysis of the dependence of the effects of therapy and treatment results on the patient’s microbiocenosis and the performed autoprobiotic therapy.
  • Study of predisposition to disease, severe course, outcome options and varying degrees of effectiveness of therapy for COVID 19.
  • Development of a vaccine for the prevention and treatment of infections caused by SARS-CoV-2.
  • Development of an innovative vaccine for the prevention of infectious complications in patients with chronic obstructive pulmonary disease.
  • Development of personalized microbial therapy for the correction of somatic pathologies (metabolic syndrome and type 2 diabetes).

MAIN RESEARCH DIRECTION

Oncology.

Study of the GURSA strain in relation to the proliferative ability of tumor cells, the expression of the main factors of metastasis, angiogenesis and immunotolerance. Studies on the use of personalized microbial therapy in patients with colorectal cancer and other neoplasms of the gastrointestinal tract and the selection of the type of autoprobiotic strain in accordance with the characteristics of the tumor and antibiotic therapy received by the patient, study of the role of microbiota in the development of tumors of the female reproductive system.

Infectious diseases and antimicrobial therapy.

Studying of a vaccine candidate preparation – a live virus-bacterial vaccine with a hemagglutinin protein modified by bacterial antigens for specific activity against influenza virus and pneumococcal infection.

Studying of the point prevalence of colonization of the respiratory tract by multidrug-resistant microorganisms in patients with COVID 19; study of the structure of the cultured microbiota of the respiratory tract of patients with coronavirus infection, differing in the severity of the clinical manifestations of this disease and the formation of a working collection of multi-antibiotic-resistant pathogens of infections associated with the provision of medical care (HAI).

Studying and screening of patients with metabolic syndrome and type 2 diabetes. The study will be accompanied by a study of the metagenome of patients before and after personalized microbial therapy.

Description of projects

  • The department employees are involved in the following projects:
  • Development and creation of oncolytic bacterial and viral strains for the treatment of intestinal and pancreatobiliary neoplasms, as well as brain tumors.
  • Development of an approach to improving the long-term results of treatment of cancer patients through personalized microbial therapy.
  • Investigation of predisposition to disease, severe course, outcome options and varying degrees of effectiveness of therapy for covid 19. Development of a vaccine for the prevention and treatment of infections caused by SARS-Cov-2.
  • Innovative vaccines for the prevention of infectious complications in patients with chronic obstructive pulmonary disease.
  • Personalized microbial therapy as an approach to the correction of somatic pathologies (metabolic syndrome and type 2 diabetes).

Structure

Laboratory of Oncolytic bacteria
Laboratory for Vaccine Prevention of Infectious Diseases
Laboratory of Personalized Microbial Therapy

Main publications of the department research assistants

  • Suvorova M.A., Kramskaya T.A., Duplik N.V., Chereshnev V.A., Grabovskaya K.B., Ermolenko E.I., Suvorov A.N., Kiseleva E.P. The effect of inactivation of the M-protein gene on the antitumor properties of living Streptococcus pyogenes in the experiment // Problems of Oncology. – 2017. – T.63, No. 5. – p. 65-69.
  • Suvorova M.A., Kramskaya T.A., Suvorov A.N., Kiseleva E.P. Inactivation of the M111 protein gene affects the interaction of Streptococcus pyogenes with mouse macrophages in vitro // Bulletin of Experimental Biology and Medicine. – 2017. – T.164, No. 9. – S. 330-334.
  • Suvorova M.A., Tsapieva A.N., Duplik N.V., Kramskaya T.A., Grabovskaya K.B., Kiseleva E.P., Chereshnev V.A., Suvorov A.N.Construction of a streptococcus strain M-protein mutant // Medical academic journal. – 2016. – Vol. 16, No. 4. – p.235-236.
  • Suvorova M.A., Kramskaya T.A., Karaseva A.B., Mukhin V.N., Ermolenko E.I., Suvorov A.N. Inactivation of the arginine deiminase gene of streptococci reduces the degree of their antitumor activity in vitro and in vivo // Medical academic journal. – 2017. – Vol. 17, No. 1. – p.96-101
  • Suvorova M., Tsapieva A., Bak E, Chereshnev V., Kiseleva E., Suvorov A., Arumugam M. Complete genome sequences of emm111 type Streptococcus pyogenes strain GUR with anti-tumor activity and it’s derivate strain GURSA1 with inactivated emm gene // Genome Announcements. – 2017. – Vol. 5, Issue 38 .– e00939-17. doi: 10.1128 / genomeA.00939-17.
  • Nikitenko NA, Mil’yan BL, Lugovkina NV, et al. Experimental comparison of Streptococcus pyogenes strain of serotype M111 and its mutant by MALDI mass spectrometry // Problems of medical mycology. – 2018. No. 2. – p. 97.
  • Zakharenko A.A., Suvorov A.N., Shlyk I.V., Ten O.A., Dzhamilov Sh.R., Natha A.S., Trushin A.A., Belyaev M.A. intestines in patients with colorectal cancer and methods of their correction (literature review) // Coloproctology. – 2016. – No. 2 (56). – p. 48-56.
  • Dyatlova A.S., Linkova N.S., Polyakova V.O., Kvetnoi I.M., Samoshkin N.G. ARID1A, prostaglandin e2, and its receptor as possible predictors of malignant transformation of the endometrium in endometriosis // Bulletin of Experimental Biology and Medicine. – 2019. Т– 167. –No. 4. –p.504-507.
  • Shamova O.V., Zharkova M.S., Kopeikin P.M., Lukyanova T.A., Artamonov A.Yu., Balandin S.V., Filatenkova T.A., Nazarov A.S., Safiullina K .E., Sukhareva M.S.,. Pazina T.Yu., Grinchuk T.M.,. Kokryakov VN, Ovchinnikova TV, Orlov DS .. Proline-rich peptides of innate immunity as prototypes of new antimicrobial and antitumor drugs // Acta nature. – 2017. – Special issue. – p. 148-149
  • Pazina T.Yu., Artamonov A.Yu., Orlov D.S., Filatenkova T.A., Shamova O.V. Effects of antimicrobial peptides on the cytotoxic activity of human peripheral blood mononuclear cells against multiple myeloma cells in vitro // Medical Immunology. – 2017 .– T. 19, Special issue. – S. 51-52.
  • Nekhaeva T.L., Chernov A.N., Toropova Ya.G., Galagudza M.M., Baldueva I.A. Tumor models of mice in testing anticancer drugs // Problems of Oncology .– 2020. – 6 (4). – p. 353-363.
  • Alexander N. Chernov, Diana A. Alaverdian, Oleg S. Glotov, Michael V. Talabaev, Stanislav P. Urazov, Sergei G. Shcherbak, Olga V. Shamova. The expression of TRKA and P75 receptors and MYC-oncogenes determine the sensitivity of brain tumor cells to the treatment with the nerve growth factor in combination with chemotherapy // Drug Metabolism and Personalized Therapy.– 2020. doi.org/10.1515/dmpt-2020 -0109.
  • Chernov A.N. Influence of nerve growth factor on the number of copies of MYCC-, MYCN-oncogenes in human medulloblastoma cells // Malignant tumors. –2019; -1. -WITH. 22-28. doi.org/10.18 027 / 2224-5057-2019-9-1-22-28.
  • Chernov A.N. Ultrastructural correlates of the mechanisms of the isolated and combined action of cisplatin, temozolomide, nerve growth factor on human astrocytoma and medulloblastoma cells // Translational Medicine. – 2019; -1. – S. 28-42. doi.org/10.18705/2311-4495-2019-6-1-27-42.
  • Chernov A.N., Barantsevich E.P., Kalyunov V.N., Galagudza M.M. Methods for in vitro selection of chemotherapy drugs for individual chemotherapy of malignant neoplasms in patients // Translational Medicine. –2018; –5 (3). –S.45–65. https://doi.org/10.18705/2311-4495-2018-5-3-45-65.
  • Zakharenko A.A., Suvorov A.N., Shlyk I.V., Ten O.A., Dzhamilov Sh.R., Natkha A.S., Trushin A.A., Belyaev M.A. Disorders of intestinal microbiocenosis in patients with colorectal cancer and methods of their correction (literature review) // Coloproctology. – 2016. No. 2 (56). – p. 48-56.
  • Bagnenko S.F., Zakharenko A.A., Suvorov A.N., Shlyk I.V., Ten O.A., Dzhamilov Sh.R., Belyaev M.A., Trushin A.A., Natha A S., Zaitsev D.A., Vovin K.N., Rybalchenko V.A. Perioperative changes in intestinal microbiocenosis in patients with colon cancer. I.I. Grekov. – 2016. – T. 175, No. 6. – p. 33-37.
  • Ermolenko E.I., Abdurasulova I.N., Kotyleva M.P., Matsulevich A.V., Karaseva A.B., Tarasova E.A., Sizov V.V., Suvorov A.N., Svirido D.A .. Effects of in
  • Suvorov A., Karaseva A., Kotyleva M., Lavrenova N., Kramskaya T., Leontieva G., Kudryavtsev I., Ermolenko E., Kondratenko Y., Korobeynikov A., Kozyrev P., Lapidus A., Guo D Autoprobiotics as an approach for restoration of personalized microbiota // Frontiers in Microbiology. –2018. -T. 9. –No SEP. -WITH. 1869.
  • Tkachenko O., Lapin S., Mazing A., Emanuel V., Belolipetskaia E., Beliaeva I., Myachikova V., Maslyansky A., Schierack P., Roggenbuck D. Profiling of non-criteria antiphospholipid antibodies in patients with sle : differentiation of thrombotic sle patients and risk of recurrence of thrombosis Lupus. –2020. -T. 29. –№5. –p. 490-498.
  • Guseva V.I., Lapin S.V., Myachikova V.Yu., Maslyansky A.L., Chukhlovin A.B., Ivanova N.E., Tkachenko O.Yu., Blinova T.V., Totolyan A .A. Clinical significance of determining the genes of the hla-drb1 locus in rheumatoid arthritis // Medical Immunology. 2019.Vol. 21.No.2. S. 333-340.
  • Tkachenko O., Lapin S., Guseva V., Mikhailova L., Maslyansky AL, Myachikova V. Yu., Belolipetskaia E., Belyaeva I., Mazurov V., Ivanova N., Gilburd B. Influence of hla-drb1 susceptibility alleles on the autoantibodies spectrum of systemic lupus erythematosus in european part of Russia // Autoimmunity Reviews. –2019. -T. 18. –№5. –С. 558-560.
  • Deodhar A., Gensler LS, Sieper J., Clark M., Calderon C., Wang Y., Zhou Y., Leu JH, Campbell K., Sweet K., Harrison DD, Hsia EC, Heijde D., Ariel F ., Asnal CA, Berman A., Citera G., Rodriguez G., Savio VG, Bird P., Griffiths H., Nicholls D., Rischmueller M., Zochling J., De Vlam K., Malaise M., Toukap AN, Van Den Bosch F., Vanhoof J., Bonfiglioli R., Keiserman M., Scotton AS, Xavier R., Ximenes AC, Atanasov A., Goranov I., Kazmin I., Licheva RN, Nikolov N., Oparanov B., Stoilov R., Bessette L., Rodrigues J., Bortilik L., Dokoupilova E., Dvoarak Z., Galatikova D., Nemec P., Podrazilova L., Simkova G., Stejfova Z., Moravcova R. , Vitek P., Cantagrel A., Baillet A., Banneville B., Combe B., Breban M., Nguyen M., Goupille P., Braun J., Everding A., Kekow J., Koenig R., Rubbert -Roth A., Witte T., Bartha A., Drescher E., Kerekes K., Kovacs A., Pulai J., Rojkovich B., Szanto S., Toth E., Avila H., Torre IG, Irazoque F ., Maradiaga M., Pacheco C., Brzosko M., Dudek A., Jeka S., Krogulec M., Kwiatkowska B., Wiland P., Wojciechowski R., Zielinska A., Santos H. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis / / Arthritis And Rheumatology.– –T. 71. –S. 258.
  • Deodhar A., Gottlieb AB, Boehncke WH, Dong B., Wang Yu., Zhuang Ya., Barchuk W., Xu XL, Hsia EC, Aelion Ja., Amarelo-Ramos Ju., Balsa A., Berghea F., Brzezicki Ja., Burnette M., Fretzin S., García-Carazo S., Gladstein G., Gomez-Reino Ju., Gooderham M. Et Al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study // The Lancet. –2018. -T. 391. – No. 10136. -S. 2213-2224.
  • Kuznetsova D.A., Lapin S.V., Gaidukova I.Z., Rebrov A.P., Maslyansky A.L. Clinical and diagnostic significance of autoantibodies to cd74 in axial spondyloarthritis // Clinical Laboratory Diagnostics. –2018. -T. 63. –No. 5. –S. 297-301.
  • Gupalova T, Leontieva G, Kramskaya T, et al. Development of experimental GBS vaccine for mucosal immunization // PLoS One. –2018. –13 (5). – e0196564. doi: 10.1371 / journal.pone.0196564
  • Desheva YA, Leontieva GF, Kramskaya TA, et al. Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection // Heliyon. –2019. –5 (2). –E01154. doi: 10.1016 / j.heliyon.2019.e01154
  • Desheva Y, Leontieva G, Kramskaya T, et al. Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections // PLoS One. – 2019. –14 (6). –E0218544 .. doi: 10.1371 / journal.pone.0218544
  • Gupalova T, Leontieva G, Kramskaya T, Grabovskaya K, Kuleshevich E, Suvorov A. Development of experimental pneumococcal vaccine for mucosal immunization // PLoS One. –2019. – 14 (6). –E0218679. doi: 10.1371 / journal.pone.0218679
  • Kramskaya T, Leontieva G, Desheva Y, et al. Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice // PLoS One. – 2019. –14 (9). –E0222148. doi: 10.1371 / journal.pone.0222148

 Patents and inventions 

  • Patent RU 2685947 C2 from 04.2019 (Application 2016152829, 30.12.2016) Recombinant strain Streptococcus pyogenes (pT7ErmEMM) – tumor growth inhibitor, authors: Suvorov A.N., Chereshnev V.A., Suvorova M.A., Duplik N. V., Kiseleva E.P., Gryaznova D.V., Tsapieva A.N.
  • Patent RU 2642246 C2 dated 01.24.2018 (Application 2014154366 dated 12.30.2014). The use of a probiotic strain of the microorganism enterococcus faecium l-3 for the treatment of neurodegenerative diseases, authors: Abdurasulova I.N., Tarasova E.A., Ermolenko E.I., Matsulevich A.V., Suvorov A.N.
  • Patent RU 2685957 C2 from 23.04.2019 (Application: 2016152455, 28.12.2016) Chimeric recombinant protein with protective properties against Streptococcus pyogenes, authors: Suvorov A.N., Dukhovlinov I.V., Leontyeva G.F., Grabovskaya K.B., Duplik N.V., Kramskaya T.A., Shevchenko V.Yu.
  • Patent RU 2701733 C1 dated 01.10.2019 (Application: 2018144657, 14.12.2018) Live vaccine based on the probiotic strain ENTEROCOCCUS FAECIUM L3 for the prevention of infection caused by STREPTOCOCCUS PNEUMONIE, authors: Suvorov A.N., Gupalova T.V., Kuleshevich E V.V., Leontyeva G.F., Kramskaya T.A., Zolotareva A.D.